Background
Low- and middle-income countries now experience the highest prevalence and mortality rates of cardiovascular disease.
Main text
While improving the availability and delivery of proven, effective therapies will no doubt mitigate this burden, we posit that studies evaluating cardiovasc...ular disease risk factors, management strategies and service delivery, in diverse settings and diverse populations, are equally critical to improving outcomes in low- and middle-income countries. Focusing on examples drawn from four cardiovascular diseases — coronary artery disease, stroke, diabetes and kidney disease — we argue that ethnicity, culture and context matter in determining the risk factors for disease as well as the comparative effectiveness of medications and other interventions, particularly diet and lifestyle interventions.
Conclusion
We believe that a host of cohort studies and randomized control trials currently being conducted or planned in low- and middle-income countries, focusing on previously understudied race/ethnic groups, have the potential to increase knowledge about the cause(s) and management of cardiovascular diseases across the world.
more
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more
Panam Salud Publica. 2021;45:e22. https://doi.org/10.26633/RPSP.2021.22
The content of these guidelines goes beyond the technicalities of medical needs with additional insights into community empowerment, possible access to welfare and economic opportunities and similar issues. If these are adequately explored, the health and quality of life of people affected and their... families would be greatly restored.
more
The WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination is intended to offer guidance on the prioritization of groups for vaccination when vaccine supply is limited. It provides a values foundation for the objectives of COVID-19 vaccination programmes and links t...hose to target groups for vaccination. This information is valuable to countries and globally while specific policies will be developed once vaccines become available.
This document it available in Arabic, Chinese English, French, Portugese and Russian,
more
Child marriage is a widespread practice across Turkana, a nomadic pastoralist region in Kenya. This report explores the issue through the voices of those girls affected by it.
South Africa has a long history of community health workers (CHWs). It has been a journey that has required balancing constrained resources and competing priorities. CHWs form a bridge between communities and healthcare service provision within health facilities and act as the cornerstone of South A...frica’s Ward-Based Primary Healthcare Outreach Teams. This study aimed to document the CHW policy implementation landscape across six provinces in South Africa and explore the reasons for local adaptation of CHW models and to identify potential barriers and facilitators to implementation of the revised framework to help guide and inform future planning.
more
Protection from a Single Dose of HPV Vaccine A major public health impact from IARC studies of vaccine efficacy.
La 3ieme édition du nouveau mini-manuel.
Au cours des mois à venir COVID Reference publiera des mises à jour régulières.
UNICEF’s Global HIV Response 2018 – 2021
Accessed: 02.11.2019
This training module is designed to equip health workers (HWs) with
knowledge, skills, confidence and resources to help them in their role to recommend the Human Papillomavirus
(HPV) vaccine.
This document accompanies the interim guidance on “Strengthening Preparedness for COVID-19 in cities and urban settings”. It provides local authorities, leaders and policy-makers in cities with a checklist tool to ensure that key areas have been covered. An excel version that local authorities m...ay wish to adapt to meet their needs is also available. It allows filtering by steps of action; suggested domains and responsible teams within local governments for each action; and phase(s) of the emergency management cycle.
more
his guidance provides interim guidance for the integration of SARS-CoV-2 and influenza virologic and genomic surveillance, from sentinel site case enrolment and sampling to the eventual sharing of the virus sequence data, a process known as end-to-end surveillance. This guidance builds on experience...s and lessons learned as countries adapted their influenza surveillance systems in the context of the COVID-19 pandemic and reviews new evidence to provide guidance on end-to-end surveillance. The guidance includes new algorithms and strategies to adapt sentinel systems to make them resilient and agile for addressing global and national surveillance needs for influenza and COVID-19.covid-
more
A GUIDE FOR HEALTH CARE PROVIDERS.
This material was reprinted, with permission, from the National Sexual Violence Resource Center’s publication entitled Assessing
patients for sexual violence: A guide for health care providers. This guide is available by visiting www.nsvrc.org